CurrentCignaPolicy N/A

Topical Podofilox Products Step Therapy Policy

Defines step therapy requirements for coverage of topical podofilox products (podofilox 0.5% solution and podofilox 0.5% gel/Condylox) for members of Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyTopical Podofilox Products Step Therapy Policy

Policy CodePolicy N/A

Change TypeMaterial — generic added to Step 2

Effective Date

Next Review DateJan 22, 2025

Key ActionProviders must document prior therapy and try Step 1 (podofilox 0.5% solution) before Step 2 will be approved unless perianal warts are present.

SourceLink

POLICY UPDATE CHANGES

The generic of Condylox (podofilox 0.5% topical gel) was added to the Policy to Step 2.

2therapy steps (Step 1 and Step 2)

1 yearapproval duration

perianal wartsautomatic approval condition

01/22/2025last review

Coverage Criteria

Initial step therapy criteria

Covered when ALL of the following are met

Step therapy prerequisites: 1) The product requested is a topical podofilox product (podofilox 0.5% topical solution or podofilox 0.5% topical gel). 2) Approvals are provided for 1 year in duration. 3) One of the following must be true: a) The patient has tried one Step 1 product (podofilox 0.5% topical solution) prior to Step 2; OR b) The patient has perianal warts (in which case podofilox 0.5% gel is approved).

Any use that does not meet these step therapy criteria or an approved exception is considered not medically necessary.

Podofilox topical products are not indicated for mucous membrane warts. Treatments intended for mucous membrane lesions are excluded from coverage under this indication; histopathologic confirmation is recommended when the diagnosis is uncertain to distinguish warts from other lesions such as squamous cell carcinoma.

Any use of topical podofilox products that does not meet the established step therapy criteria or an approved exception is considered not medically necessary and will not be covered.

Initial Therapy

Policy Summary

PayerCigna

PolicyTopical Podofilox Products Step Therapy Policy

Policy CodePolicy N/A

Change TypeMaterial — generic added to Step 2

Effective Date

Next Review DateJan 22, 2025

Key ActionProviders must document prior therapy and try Step 1 (podofilox 0.5% solution) before Step 2 will be approved unless perianal warts are present.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy step requirements

Step sequence for initial therapy

Required prior trial: Patient must have tried one Step 1 product (podofilox 0.5% topical solution) before a Step 2 product (podofilox 0.5% topical gel) will be approved, unless the perianal warts exception applies.1 trial

Policy: 'If the patient has tried one Step 1 Product, approve a Step 2 Product.'

Continuation Therapy

Continuation therapy

Authorization duration and continuation

Continuation approvals: Authorizations are provided for 1 year in duration. Continuation beyond the initial approval requires documentation that the patient continues to meet the same step therapy criteria or has a documented clinical need/exception (e.g., perianal warts allowing gel without prior Step 1 trial).1 year

All approvals are provided for 1 year in duration per policy statement.

Provider Actions and Requirements

Step Therapy

Step therapy requirement and approval duration

Step therapy applies. Approvals are provided for 1 year in duration.

Step therapy must be followed at point of service for Step 2 products unless an exception applies.

Documentation Required

Documentation of prior therapy and indication

Document prior therapy attempts and the clinical indication in the medical record and in any prior authorization submission per the member's benefit plan.

Include dates, dosage/formulation, response or intolerance, and reason for switching or escalation.
Reference the specific benefit plan when submitting documentation.

Step Therapy

Step therapy sequence and conditions

Step 1 is podofilox 0.5% topical solution. Step 2 is podofilox 0.5% topical gel (Condylox, generic). If the patient has tried one Step 1 product, a Step 2 product should be approved. If the patient has perianal warts, approve podofilox 0.5% gel.

Step 1 must be tried before Step 2 unless an approved exception applies.
Approval for Step 2 is authorized when documentation shows trial of one Step 1 product or presence of perianal warts.

Denial Risk

Step therapy noncompliance may trigger denial

Coverage for a Step 2 product may be denied if Step Therapy criteria are not met at point of service. Providers should ensure required documentation is available to avoid denial.

Denial risk applies when no documentation of Step 1 trial or applicable clinical exception is provided.

Step Therapy Details

Step	Requirement / Notes	Coverage
Step 1: podofilox 0.5% topical solution
Must be attempted before Step 2 except when the patient has perianal warts (see Step 2 exception). Approvals are provided for 1 year.
Covered when criteria met

Step	Product / Condition	Coverage
Step 2: podofilox 0.5% topical gel (Condylox, generic)
May be approved after the patient has tried one Step 1 product (podofilox 0.5% solution) OR when the patient has perianal warts (automatic approval for gel).
Covered when criteria met

Definitions

External genital warts

DefinitionLesions caused by human papillomavirus for which topical podofilox (gel or solution) is indicated.

Perianal wartsPerianal warts are specifically indicated for treatment with podofilox 0.5% topical gel (Condylox and generic).

Mucous membrane wartsPodofilox gel and podofilox solution are not indicated for the treatment of mucous membrane warts.

Diagnostic confirmationHistopathologic confirmation is recommended when there is doubt in diagnosis to differentiate from squamous cell carcinoma (Bowenoid papulosis).

Pediatric useSafety and effectiveness in pediatric patients have not been established for either product.

Background

Podofilox topical formulations are topical antimitotic agents indicated for the treatment of external genital warts; additionally, the podofilox 0.5% gel formulation is indicated for perianal warts. The policy defines a step therapy sequence where podofilox 0.5% topical solution is Step 1 and podofilox 0.5% topical gel (Condylox and generic) is Step 2; approvals are provided for 1 year when criteria are met.